Figure 5.

Validation of gene signature in the testing group. (A) Survival curve of high- and low-risk groups separated by gene signature. (B) ROC analysis for survival rate predicted by gene signaturefor 1-, 3-, and 5-year follow-ups. (C–E) Expression heatmap of eight signature genes (C), risk score distribution (D), and survival status of patients (E). The risk score based on gene signature in the testing group also appears to be correlated with survival status for lung cancer patients in low- and high-risk groups, which was consistent with that in training group.